

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Dexamethasone Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B H360D: May damage the unborn child.
Long-term (chronic) aquatic hazard, Category 3 H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H412 Harmful to aquatic life with long lasting effects.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:

Dexamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

| Chemical name | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) |
|----------------|---|--|--------------------------|
| Benzyl alcohol | 100-51-6 202-859-9 603-057-00-5 | Acute Tox. 4; H302 Acute Tox. 4; H332 Eye Irrit. 2; H319 Acute toxicity estimate Acute oral toxicity: 1,620 mg/kg | 1.04 |
| Dexamethasone | 50-02-2 200-003-9 | Repr. 1B; H360D STOT RE 2; H373 (Adrenal gland, Im- | 0.3 |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

| | | | |
|--|--|---|--|
| | | mune system, thy- mus gland) Aquatic Chronic 1; H410 | |
| | | M-Factor (Chronic aquatic toxicity): 1 | |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : May damage the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate contain-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

| Components | CAS-No. | Value type (Form of exposure) | Control parameters | Basis |
|---------------------------|---------|-------------------------------|------------------------------|----------|
| Dexamethasone | 50-02-2 | TWA | 10 µg/m ³ (OEB 3) | Internal |
| Further information: Skin | | | | |
| | | Wipe limit | 100 µg/100 cm ² | Internal |

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| Substance name | End Use | Exposure routes | Potential health effects | Value |
|----------------|-----------|-----------------|----------------------------|-----------------------|
| Benzyl alcohol | Workers | Inhalation | Long-term systemic effects | 22 mg/m ³ |
| | Workers | Inhalation | Acute systemic effects | 110 mg/m ³ |
| | Workers | Skin contact | Long-term systemic effects | 8 mg/kg bw/day |
| | Workers | Skin contact | Acute systemic effects | 40 mg/kg bw/day |
| | Consumers | Inhalation | Long-term systemic effects | 5.4 mg/m ³ |
| | Consumers | Inhalation | Acute systemic effects | 27 mg/m ³ |
| | Consumers | Skin contact | Long-term systemic effects | 4 mg/kg bw/day |
| | Consumers | Skin contact | Acute systemic effects | 20 mg/kg bw/day |
| | Consumers | Ingestion | Long-term systemic effects | 4 mg/kg bw/day |
| | Consumers | Ingestion | Acute systemic effects | 20 mg/kg bw/day |

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name | Environmental Compartment | Value |
|----------------|---------------------------|------------------------------|
| Sodium citrate | Fresh water | 0.44 mg/l |
| | Marine water | 0.044 mg/l |
| | Sewage treatment plant | 1000 mg/l |
| | Fresh water sediment | 34.6 mg/kg dry weight (d.w.) |
| | Marine water | 3.46 mg/kg dry weight (d.w.) |
| | Soil | 31.1 mg/kg dry weight (d.w.) |
| Benzyl alcohol | Fresh water | 1 mg/l |
| | Marine water | 0.1 mg/l |
| | Intermittent use/release | 2.3 mg/l |
| | Sewage treatment plant | 39 mg/l |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

| | | |
|--|----------------------|-------------|
| | Fresh water sediment | 5.27 mg/kg |
| | Marine sediment | 0.527 mg/kg |
| | Soil | 0.456 mg/kg |

8.2 Exposure controls

Engineering measures

Minimize workplace exposure concentrations.
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

- Eye/face protection : Wear the following personal protective equipment:
Safety glasses
Equipment should conform to I.S. EN 166
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
- Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 14387
- Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- Physical state : liquid
- Colour : white to off-white
- Odour : No data available
- Odour Threshold : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

| | | |
|--|---|-------------------|
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Flash point | : | No data available |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| pH | : | 7.0 - 7.8 |
| Viscosity | | |
| Viscosity, kinematic | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Vapour pressure | : | No data available |
| Density | : | No data available |
| Relative vapour density | : | No data available |
| Particle characteristics | | |
| Particle size | : | No data available |

9.2 Other information

| | | |
|----------------------|---|--|
| Explosives | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Evaporation rate | : | No data available |
| Molecular weight | : | No data available |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:

Benzyl alcohol:

Acute oral toxicity : LD50 (Rat): 1,620 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 4.178 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

Dexamethasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 6,500 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 14 mg/kg
Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Dexamethasone:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irritation to eyes, reversing within 21 days

Dexamethasone:

Species : Rabbit
Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Benzyl alcohol:

Test Type : Maximisation Test
Exposure routes : Skin contact

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Benzyl alcohol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Dexamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro assay
Test system: mouse lymphoma cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Benzyl alcohol:

Species : Mouse
Application Route : Ingestion
Exposure time : 103 weeks
Method : OECD Test Guideline 451
Result : negative

Reproductive toxicity

May damage the unborn child.

Components:

Benzyl alcohol:

Effects on fertility : Test Type: Fertility/early embryonic development

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Ingestion
Result: negative

Dexamethasone:

Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 6 mg/kg body weight
Result: Specific developmental abnormalities, Cleft palate

Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: NOAEL: 0.025 mg/kg body weight
Result: Specific developmental abnormalities

Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: \geq 0.062 mg/kg body weight
Result: Specific developmental abnormalities

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: \geq 0.02 mg/kg body weight
Result: Skeletal and visceral variations, Retardations

Reproductive toxicity - Assessment : May damage the unborn child.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Dexamethasone:

Exposure routes : Oral
Target Organs : Adrenal gland, Immune system, thymus gland
Assessment : May cause damage to organs through prolonged or repeated exposure.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

Repeated dose toxicity

Components:

Benzyl alcohol:

Species : Rat
NOAEL : 1.072 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 28 Days
Method : OECD Test Guideline 412

Dexamethasone:

Species : Rat
NOAEL : 0.0015 mg/kg
Application Route : Oral
Exposure time : 7 d
Target Organs : Liver
Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.003 mg/kg
Application Route : Oral
Exposure time : 90 d
Target Organs : Blood, Adrenal gland, thymus gland
Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.125 mg/kg
Application Route : Oral
Exposure time : 6 Weeks
Target Organs : Adrenal gland
Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.4 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system
Remarks : Significant toxicity observed in testing

Species : Dog
LOAEL : 8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system
Remarks : Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Dexamethasone:

Ingestion : Target Organs: Immune system
Target Organs: Adrenal gland
Target Organs: Bone
Symptoms: muscle weakness

SECTION 12: Ecological information

12.1 Toxicity

Components:

Benzyl alcohol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 460 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 230 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 51 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Dexamethasone:

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 56 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

| | | |
|-------------------------------------|---|--|
| aquatic invertebrates | | Exposure time: 48 h Method: OECD Test Guideline 202 |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 9.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Toxicity to microorganisms | : | EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC : 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |
| Toxicity to fish (Chronic toxicity) | : | NOEC: 0.033 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210 |
| M-Factor (Chronic aquatic toxicity) | : | 1 |

12.2 Persistence and degradability

Components:

Benzyl alcohol:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 - 96 %
Exposure time: 14 d

Dexamethasone:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 3.54 d
Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

Components:

Benzyl alcohol:

Partition coefficient: n-octanol/water : log Pow: 1.05

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

Dexamethasone:

Partition coefficient: n-octanol/water : log Pow: 1.83

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

14.2 UN proper shipping name

| | | |
|------|---|-----------------------------------|
| ADN | : | Not regulated as a dangerous good |
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

14.3 Transport hazard class(es)

| | | |
|------|---|-----------------------------------|
| ADN | : | Not regulated as a dangerous good |
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

14.4 Packing group

| | | |
|------------------|---|-----------------------------------|
| ADN | : | Not regulated as a dangerous good |
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA (Cargo) | : | Not regulated as a dangerous good |
| IATA (Passenger) | : | Not regulated as a dangerous good |

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

| | | |
|--|---|---|
| REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) | : | Conditions of restriction for the following entries should be considered: Number on list 75, 3 |
|--|---|---|

If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

Version 3.1 Revision Date: 30.09.2023 SDS Number: 1843087-00014 Date of last issue: 04.04.2023
Date of first issue: 20.07.2017

here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H332 : Harmful if inhaled.

H360D : May damage the unborn child.

H373 : May cause damage to organs through prolonged or repeated

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

H410 : exposure if swallowed.
: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 1B H360D
Aquatic Chronic 3 H412

Classification procedure:

Calculation method
Calculation method

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Dexamethasone Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 3.1 | 30.09.2023 | 1843087-00014 | Date of first issue: 20.07.2017 |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN